Vernalis Plc Announces FDA Acceptance For Filing Of Frova(R) For Short-Term Prevention Of Menstrual Migraine

Thu, 21 Sep 2006 12:00 PM EST

... Vernalis plc (LSE: VER, Nasdaq: VNLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Frova(R) (frovatriptan succinate) 2.5 mg tablets for the short-term (six days per month) prevention of menstrual migraine (MM). [click link for full article] ...